secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prelude Therapeutics Inc (PRLD)
CIK:        0001678660
Form:       8-K
Filed at:   2026-06-10T20:11:13+00:00
Accession:  0001193125-26-265835
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Prelude Therapeutics annual meeting: all director nominees elected, auditor ratified, say-on-pay approved
--------------------------------------------------------------------------------

- Elected Krishna Vaddi, Paul Scherer, Katina Dorton as Class III directors with over 26.9M shares for each.
- Ratified Ernst & Young LLP as independent auditor for FY2026 with 31,841,080 shares for, 4,951 against.
- Advisory vote to approve 2025 named executive officer compensation passed with 26,869,142 shares for.
- Stockholders selected '1 Year' as frequency for future say-on-pay votes with 26,877,941 votes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1678660/000119312526265835/0001193125-26-265835-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1678660/000119312526265835/prld-20260609.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-265835

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer